Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Developing neuroprotective drugs for glaucoma no easy task
Neuroprotection is a concept that originated in the CNS community with the development of therapies aimed at preventing or retarding the manifestations of disorders such as Parkinson's and Alzheimer's diseases, stroke, and head trauma. Less than 15 years ago, the ophthalmic community began to discuss this concept as a novel way to preserve vision in disorders of the retina.
Related Videos
Related Content
